

Late Life Depression

Divya Hedgren, MD
Assistant Professor – Clinical
Department of Psychiatry
The Ohio State University Wexner Medical Center

Introduction

- . 13.3% of the U.S. population is an older adult**
- . The older population (age 65 year old and older)= 41.4 million in 2011, an increase of 6.3 million or 18% since 2000.**
- . Projected to increase to 79.7 million in 2040**
- . The very old (85+) projected to increase from 5.7 million in 2011 to 14.1 million in 2040**

Introduction

- . With our population aging, we will need to be prepared to provide care for medical as well as mental health issues such as depression in the older adult**
- . Most older adults with depression will be treated in the primary care setting**
- . Depression is not thought to be a normal part of aging**

Types of Depressive Disorders

- . Major depressive disorder**
- . Persistent depressive disorder (Dysthymia)**
- . Other specified depressive disorder**

Major Depressive Disorder

- . **DSM V Criteria**
- . **A. Five (or more) of the following symptoms have been present during the same 2 week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure**
 - 1. Depressed mood most of the day, nearly every day
 - 2. Markedly diminished interest or pleasure (subjective account or observation)
 - 3. Significant weight loss/gain (5%change in 1 month), or decrease/increase in appetite nearly every day
 - 4. Insomnia or hypersomnia
 - 5. Psychomotor agitation or retardation nearly every day (observed by others)

Major Depressive Disorder

- 6. Fatigue or loss of energy
- 7. Feelings of worthlessness or excessive or inappropriate guilt
- 8. Diminished ability to think or concentrate, or indecisiveness
- 9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or suicide attempt, or SI with plan

Major Depressive Disorder

- . **B. Symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning**
- . **C. The episode is not attributable to the physiological effects of a substance or to another medical condition**
- . **D. Not due to another psychiatric condition**
- . **E. There has never been a manic/hypomanic episode**

Rule Out History of Manic/Hypomanic Symptoms

- . **Periods of time when the patient experiences:**
 - **Elevated mood/irritability**
 - **Inflated self-esteem**
 - **Decreased need for sleep**
 - **Talkativeness**
 - **Flight of ideas**
 - **Risky behaviors**
 - **Increase in goal directed behaviors**

Persistent Depressive Disorder (Dysthymia)

- **A. Depressed mood for most of the day, for more days than not, as indicated by either subjective account or observation by others for at least 2 years**
- **B. Presence, while depressed, of two (or more) of the following:**
 - **1. Poor appetite or overeating**
 - **2. Insomnia or hypersomnia**
 - **3. Low energy or fatigue**
 - **4. Low self-esteem**
 - **5. Poor concentration or difficulty making decisions**
 - **6. Feelings of hopelessness**

Persistent Depressive Disorder

- **C. During the 2 year period, individual has not been without the symptoms in Criteria A and B for more than 2 months**
- **D. Criteria for a major depressive disorder may be continuously present for 2 years**
- **E. There has never been a manic episode or a hypomanic episode and criteria have never been met for cyclothymia**

Other Specified Depressive Disorder

- **Symptoms of depression are clinically significant leading to distress or impairment**
- **Full criteria for the other disorders are not met**

Bereavement

- **Normal reaction to death of loved one**
- **May present with characteristics similar to major depressive episode such as insomnia, poor appetite, and weight loss**
- **Normal grief may occur in waves or “pangs”**
- **Abnormal grief reaction: suicidal ideation, feelings of worthlessness, feelings of guilt, psychotic symptoms**

Difference between Grief and MDD

Bereavement/Grief

- Emptiness and loss
- Decrease in intensity over days/weeks or in waves
- Triggered by thoughts of deceased; Preoccupat on with thoughts of deceased
- Uncharacteristic times of happiness
- Self-esteem preserved
- Thoughts of “joining” the deceased

MDD

- Persistent depressed mood, anhedonia
- More persistent
- Not tied to thoughts of the deceased
- Pervasive unhappiness
- Feelings of worthlessness and self-loathing
- Suicidal thoughts due to worthlessness, undeserving life, and unable to cope with depression

Epidemiology

- General community dwelling elderly: 8-16% (MDD)
- Lower prevalence than adults due to “forgetting” prior episodes, under-reporting of “depressed mood”, stigma of mental illness in older cohorts
- Medically hospitalized: 11% (MDD), 25% (clinically significant depression)
- LTCF: 12-22.4% (MDD), 17-30% for minor depression

Late Onset vs Early Onset Depression

- **Late Onset: defined as first episode of depression in late life.**
- **Characterized by:**
 - **Less frequent family history**
 - **Higher likelihood of cognitive impairment**
 - **Increase in medical co-morbidities**

Risk Factors for depression

- **Female > Male**
- **Physical disability**
- **Sensory impairment**
- **Recent loss**
- **Social isolation**

Morbidity and Mortality

- . Increase in utilization of medical services**
- . Increase in use/number of medications**
- . Increase in functional impairment**
- . Increased risk for suicide**
- . Increased risk for mortality**

Suicide in the Elderly

- . 8,168 individuals aged 60 years old + died from suicide in 2010**
- . Rate of completed suicide is highest in white, elderly men**
- . 50.8 suicides per 100,000 in non-hispanic men over age 85 years old which is 4x higher than general population rate of 12.1 per 100,000**
- . Overall suicidal ideation and attempted suicide decrease with age in both men and women**

Risk Factors for Suicide

- . Male**
- . History of mental illness and/or substance abuse**
- . Prior suicide attempts**
- . Marked feelings of hopelessness**
- . Co-morbid general medical conditions that significantly limit functioning or life expectancy**
- . Pain and declining role function (e.g., loss of independence or sense of purpose)**

Risk Factors for Suicide

- . Social isolation**
- . Family discord or losses**
- . Inflexible personality or marked difficulty adapting to change**
- . Access to lethal means (e.g., firearms)**
- . Impulsivity in the context of cognitive impairment**

Presentation in the older adult

- **Less endorsement of “sad” mood (cohort effect)**
- **More likely to show lack of interest or positive affect**
- **Increased concern about physical disability and cognitive impairment**
- **Increase in somatic complaints (focus on GI symptoms, headaches)**
- **Increase in thoughts about death**
- **Increase in psychotic symptoms with focus on persecution, somatic issues, nihilistic**

Depression and Cognitive Impairment

- **Depression as a prodrome or clinical sign of dementia**
- **Depression as a risk factor for dementia**
 - **Conflicting evidence**
- **Dementia as a risk factor for depression**
- **Depression with reversible dementia or “Pseudodementia”**
 - **In one study by Alexopoulos, 1993: Patients with depression with “reversible dementia” had 4.69x higher risk of conversion to dementia (43%) within 2-3 years compared to depression alone (12%)**

Reference:

Alexopoulos, GS, Myers BS, Young RC, Mattis S, Kakuma T. The course of geriatric depression with “reversible dementia”: a controlled study. Am J Psychiatry. 1993;150(11):1693-1699.

Depression and Cognitive Impairment

- **Co-occurrence of depression and cognitive impairment associated with greater cognitive decline, functional decline and higher rates of institutionalization**
- **Depressed older adults have difficulties in executive function, processing speed, and memory**
- **Poor processing speed and small hippocampal volumes may predict poor response to antidepressant treatment**

Neurobiology of depression

- **Monoamine deficiency hypothesis**
- **Hypothalamic pituitary axis**
- **Inflammation**

Bidirectional relationship between depression and medical illness

- . Depression is a risk factor for chronic illnesses such as cardiovascular disease and diabetes**
- . Chronic illnesses such as CHF, CAD, OA, Diabetes, and stroke can increase the risk for depression**
- . Inflammation and maladaptive behaviors (poor diet, sedentary lifestyle) can be the result of depression/chronic illness which predisposes an individual to further medical illness and impairment**

Screening

- . PHQ (Patient Health Questionnaire) 2 or 9**
- . Geriatric Depression Scale (short or long)**
- . Cornell Depression Scale in Dementia**
- . Suicide: Do you have thoughts of death? Do you have plans to harm yourself?**
 - Do you have access to firearms? Do have intent to harm yourself**
 - Would you call the clinic/911/family/suicide hotline if feeling unsafe?**

Geriatric Depression Scale

- . Choose the best answer for how you have felt over the past week:
- . 1. Are you basically satisfied with your life? YES / NO
- . 2. Have you dropped many of your activities and interests? YES / NO
- . 3. Do you feel that your life is empty? YES / NO
- . 4. Do you often get bored? YES / NO
- . 5. Are you in good spirits most of the time? YES / NO
- . 6. Are you afraid that something bad is going to happen to you? YES / NO
- . 7. Do you feel happy most of the time? YES / NO
- . 8. Do you often feel helpless? YES / NO
- . 9. Do you prefer to stay at home, rather than going out and doing new things? YES / NO
- . 10. Do you feel you have more problems with memory than most? YES / NO

Geriatric Depression Scale

- . Choose the best answer for how you have felt over the past week:
- . 11. Do you think it is wonderful to be alive now? YES / NO
- . 12. Do you feel pretty worthless the way you are now? YES / NO
- . 13. Do you feel full of energy? YES / NO
- . 14. Do you feel that your situation is hopeless? YES / NO
- . 15. Do you think that most people are better off than you are? YES / NO

Geriatric Depression Scale

- **A score > 5 points is suggestive of depression.**
- **A score \geq 10 points is almost always indicative of depression.**
- **A score > 5 points should warrant a follow-up comprehensive assessment.**
- **Source:**
<http://www.stanford.edu/~yesavage/GDS.html>
- **Answers in bold indicate depression. Score 1 point for each bolded answer.**
- **This scale is in the public domain**

Screening Cognition

- **Mini Mental Status Examination**
- **Montreal Cognitive Assessment**
- **Orientation questions**

Late Life Depression

Katherine Brownlowe, MD
Assistant Professor – Clinical
Department of Psychiatry
The Ohio State University Wexner Medical Center

Assessment

- . Review diagnostic criteria for MDD**
- . Review prior history of depressive episodes, suicidal thoughts/attempts, and treatments**
- . Rule out mania, grief reaction, and substance abuse**
- . Assess functional impairment: ADLs and IADLs**
- . Assess psychosocial stressors**
- . Assess suicidal thinking and access to firearms**
- . Assess severity of symptoms**
- . Obtain collateral information from family/friends/caregivers**

Assessment

- Review medical problems and physical examination
- Review medication list including herbals/over the counters
- Family history of depression and suicide
- Obtain collateral information from family/friends/caregivers

Assessment

- Consider baseline labwork if not done recently, including CBC, Chem 7, LFTS, TFTs, UA, UDS, EKG, B12/Folate, Vit D 25-OH
- For cognitive impairment, consider RPR, HIV, homocysteine
- Consider neuroimaging, EEG
- MMSE, MOCA
- Consider sleep study

Medication induced depression

- **Corticosteroids**
- **Benzodiazepines**
- **Oral contraceptives**
- **Alpha-interferon**
- **Tamoxifen**
- **Chantix**
- **Anticonvulsants (Keppra)**

Treatment: Expert Consensus Guidelines

Expert Consensus Guidelines in 2001:

- **Nonpsychotic MDD:
SSRI/SNRI(Venlafaxine) + Psychotherapy**
- **Psychotic MDD: SSRI/SNRI (Venlafaxine)
+ Atypical antipsychotic or ECT**
- **MDD + Medical disorder: treat both**
- **Dysthymic do: SSRI + Psychotherapy**

Expert Guidelines: Treatment Duration

- **One episode: 1 year**
- **Two episodes: 1-3 years**
- **3 or more episodes: lifelong**

Treatment: Pharmacotherapy

- **Serotonin reuptake inhibitors (SSRIs) and Serotonin norepinephrine reuptake inhibitors (SNRIs such as Venlafaxine) are first line antidepressants. They are equally efficacious and tolerable in recent studies**
- **Other options include mirtazapine and bupropion**
- **Tricyclic antidepressants (TCAs) may be used if SSRIs/SNRIs are not beneficial; however, there is greater risk for side effects and intolerability.**
- **Monoamine oxidase inhibitors (MAOIs)**

Pharmacotherapy

- **Start at low dose to ensure tolerability**
- **Adequate trial is 8 weeks at therapeutic dose (which may be adult dose)**
- **Dose increase after 4-6 weeks in partial responders. If no response, consider switch or augmentation**
- **Be aware of drug-drug interactions (several antidepressants including paroxetine, fluoxetine and bupropion are strong 2D6 inhibitors)**
- **Be aware of medical co-morbidities**
- **Goal is to reach remission of symptoms to decrease risk for future relapse**

SSRIs

- **Side Effects include: anxiety/agitation, tremor, headaches, diarrhea, nausea, dizziness, sleep changes, hyponatremia (SIADH), sexual dysfunction, decrease in platelet aggregation**
- **Precautions: QTc prolonging effect with citalopram and escitalopram**

SSRI	Starting dose	Dose range per day
Citalopram	10mg	10-20mg
Escitalopram	5mg	5-20mg
Sertraline	12.5 to 25mg	50 - 100mg
Paroxetine	10mg	10mg - 40mg
Fluoxetine	5-10mg	10-40mg

SNRIs

- **Side Effects:** headache, nausea, anxiety/agitation, tremors, sexual dysfunction, hyponatremia, decrease in platelet aggregation due to serotonin effects
- **Precautions:** risk for increase in diastolic blood pressures, hepatotoxicity with duloxetine
- **Helpful in pain syndrome**

SNRI	Starting dose	Dose Range	Frequency	
Venlafaxine	37.5mg	75 - 225mg	Daily or BID	
Duloxetine	20-30mg	60mg	Daily	

Other Antidepressants

- **Bupropion**
 - Increases dopamine and norepinephrine.
 - Start at 37.5mg, range from 75mg to 300mg daily (once daily or split dosing).
 - Avoid in patients with eating disorders, high anxiety/agitation, and seizures.
 - Side effects are sleep disturbances, elevations in blood pressure, and anxiety/agitation.

Other Antidepressants

- **Mirtazapine**
 - Increases serotonin and norepinephrine
 - Start at 7.5 to 15mg, range from 15 to 45mg, once nightly
 - May promote appetite, weight gain, and sedation
 - Does not decrease platelet aggregation, sexual dysfunction, and has less risk for nausea
 - Monitor for neutropenia/agranulocytosis

Tricyclic Antidepressants

- **Side effects: risk for cardiac conduction abnormalities, anticholinergic issues (constipation, dry mouth, urinary retention), orthostasis, dizziness, sedation**
- **Monitor EKG**
- **Avoid in prostatic hypertrophy and narrow-angle glaucoma**
- **Can be lethal in overdose**
- **Nortriptyline: least orthostatic of TCAs, start at 10mg, range is 10-125mg, monitor blood levels (range is 50-150)**
- **Desipramine: least anticholinergic of TCAs, start at 10mg, range is 100-200mg**

Monoamine Oxidase Inhibitors

- . Emsam (Selegiline patch)**
- . Do not use with other serotonergic agents**
- . Washout of at least 2 weeks with other antidepressants, 5 weeks for Prozac**
- . Dietary restrictions with higher doses**
- . Limited data in older adults**

Serotonin Syndrome

- . Elevated levels of serotonin can lead to serotonin syndrome, which can be life-threatening**
- . Signs /symptoms are loose stools, vomiting, elevated heart rate/blood pressure, agitation, myoclonus, ocular clonus, deep tendon hyperreflexia, confusion, tremor, dilated pupils, muscle rigidity, dry mucous membranes, flushed skin and diaphoresis**
- . Medications that can lead to this include: antidepressants, opiates, linezolid, demerol, dextromethorphan, triptans, ultram**
- . Discontinue serotonergic agents, provide supportive care, possible use of cyproheptadine**

Pharmacotherapy Response

- . 30 to 50% of older adults will not respond to treatment with SSRIs**
- . 40-50% of non-responders will respond to non-SSRI treatments such as switching to SNRI or augmentation strategies such as adding Bupropion, Lithium or T3**

Treatment: Psychotherapy

- . Psychotherapy is an effective treatment in older adults with depression**
- . Studies utilizing Cognitive Behavioral Therapy, Interpersonal Therapy, Problem-Solving Treatment, Supportive Psychotherapy can be helpful as they are directive and usually time limited treatments**
- . Behavioral activation and schedule management assistance can be helpful as well**

Treatment: Psychotherapy

- **Psychotherapy can be equally efficacious as medications for treatment of depression**
- **Choice between therapy and medications will be based on access to care, cost, possible medication adverse effects/tolerability**
- **Combination of Pharmacotherapy + Psychotherapy reduces risk of relapse compared to either treatment alone**

Treatment: Other therapies

- **Exercise**
- **Senior centers**
- **In-home caregivers**
- **Bright light therapy**
- **Family counseling**

Treatment: Neuromodulation therapies

- **Electroconvulsive therapy (ECT)**
 - Effective treatment for severe depression in the elderly
 - Thought to be more effective in older adults
 - Age is not necessarily a risk factor for cognitive side effects.
 - Risk factor for cognitive side effects include female gender, neurological disease such as AD, PD, cerebrovascular disease, low premorbid intellectual capacity
 - Dementia is not a contraindication for ECT
 - Remission rates 50-80%
 - However, relapse rate within 6 to 12 months is 50% (all ages), as high as 80% relapse with no medication treatment following ECT

Treatment: Neuromodulation therapies

rTMS—FDA approved for treatment-resistant depression

- **Repetitive electromagnetic delivered to dorsolateral prefrontal cortex daily x4-6 weeks**
- **Improves blood flow and neurotransmitter release; changes in cortical metabolism**
- **Effective for older adults, and treatment can be modified at a lower frequency for improved tolerability**

Refractory Depression

- . Review accuracy of your diagnosis – consider additional history and medical work-up (reconsider dementia, bipolar disorder, another medical condition)**
- . Multiple medication trials may be needed before reaching remission of symptoms**
- . Refer to psychiatrist for psychosis, multiple med trial failures, suicide risk**
- . Consider referral for Neuropsychological testing**

Key Points

- 1. Older adults may not endorse sad mood but rather lack of interest and appear to have a negative affect**
- 2. Rule out medical conditions first**
- 3. Rule out history of mania/hypomania and substance abuse**
- 4. Obtain collateral information**
- 5. Perform a baseline cognitive assessment**

Key Points

- 6. Assess for safety in terms of suicide risk, access to firearms, and functional impairment**
- 7. Treatment responses to psychotherapy and pharmacotherapy are similar to general adult population but caution should be taken with dosing and medical co-morbidities**
- 8. Refer for hospitalization for risk of harm to self/others**
- 9. Refer to psychiatrist for severe illness, refractory depression, or psychotic depression**
- 10. Refer to cognitive specialist for concerns about cognitive impairment**

Resources for Patients and Caregivers

- . Geriatric Mental Health Foundation (GMHF)**
- . National Alliance on Mental Illness (NAMI)**
- . National Institute of Mental Health (NIMH)**

References

- Abraham G1, Milev R, Lazowski L, Jokic R, du Toit R, Lowe A. Repetitive transcranial magnetic stimulation for treatment of elderly patients with depression - an open label trial
- Alexopoulos, GS. Pharmacotherapy for late-life depression. J Clin Psychiatry. 2011 Jan;72(1):e04. Retrieved on March 21, 2014 from <http://www.ncbi.nlm.nih.gov/>
- American Psychiatric Association: Desk Reference to the Diagnostic Criteria From DSM-5. Arlington, VA, American Psychiatric Association, 2013 Neuropsychiatr Dis Treat. Dec 2007; 3(6): 919–924.
- Boyer, E. (2013, Sept 9). Serotonin syndrome. Uptodate. Retrieved March 21, 2014, from www.Uptodate.com.
- Blazer, D. and D. Steffens. (2009). *Textbook of geriatric psychiatry, fourth edition*. Washington, D.C. American Psychiatric Publishing, Inc.
- Conwell, Y. Suicide and suicide prevention in later life. Focus. 2013 Winter;11(1):39-47.

References

- Cooper, C., et al. A systematic review of treatments for refractory depression in older people. Focus. Winter 2013; Vol. XI, No 1.
- Flint AJ and Gagnon N, Can J Psychiatry. 2002 Oct;47(8):734-41
- Lenze, E., et al. Incomplete response in late-life depression: getting to remission. Dialogues Clin Neurosci. Dec 2008; 10(4): 419–430.
- Older americans behavioral health, issue brief 4: Preventing Suicide in Older Adults. Administration on aging website. Retrieved on March 28, 2014 from:
http://www.aoa.gov/AoARoot/AoA_Programs/HPW/Behavioral/docs/Older%20Americans%20Issue%20Brief%204_Preventing%20Suicide_508.pdf
- Pallanti S., et al. rTMS age-dependent response in treatment-resistant depressed subjects: a mini-review. CNS Spectr. 2012 Mar;17(1):24-30.

References

- **Potter, G.G. and Steffens, D.C. Contribution of Depression to Cognitive Impairment and Dementia in Older Adults. *The Neurologist*. 2007; 13(3):105-117.**
- **Sackeim HA et al., *Neuropsychopharm*. 2007; 32(1):244-54**
- **Sadavoy, J., et al. (2004). *Comprehensive textbook of geriatric psychiatry, third edition*. New York. W.W. Norton and Company.**
- **Steffens, D.C, et al. Treatment course with antidepressant therapy in late-life depression. *Am J Psychiatry*. 2012. 169:1185-1193.**
- **Unutzer, J., et al. Older Adults With Severe, Treatment-Resistant Depression. *JAMA*. 2012;308(9):909-918.**